Beneficial Ownership Report · SCHEDULE 13G/A
Scholar Rock Holding Corporation
SRRKNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- SCHOLAR ROCK HOLDING CORP
- Company CIK
- 0001727196
- Street
- 301 BINNEY STREET
- Street (continued)
- 3RD FLOOR
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02142
Statement details
- Amendment number
- 9
- Security class
- COMMON STOCK
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- T. Rowe Price Associates, Inc.
- Citizenship / organization
- MD
- Reporting person type
- IA
- Aggregate amount owned
- 5,865,988
- Percent of class
- 4.8
- Sole voting power
- 5,861,872
- Shared voting power
- 0
- Sole dispositive power
- 5,865,988
- Shared dispositive power
- 0
- Aggregate excludes certain shares
- N
Item 1
Issuer
SCHOLAR ROCK HOLDING CORP
Principal executive office address
301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142
Item 2
Citizenship
Maryland
Filing person
T. Rowe Price Associates, Inc.
Principal business or residence address
1307 Point Street, Baltimore, MD 21231
Item 3
Not applicable indication
N
Type of filing person
IA
Item 4
Percent of class
4.8
Amount beneficially owned
5865988
Sole voting power
5861872
Shared voting power
0
Sole dispositive power
5865988
Shared dispositive power
0
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
Signature 1
- Reporting person
- T. Rowe Price Associates, Inc.
- Signed
- Ellen York
- Title
- Vice President
- Date
- 11/16/2026
Company context
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Following FDA approval in September 2026, Scholar Rock is commercializing ISEMBLYD (apitegromab-mstn) in the U.S. for people living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. The Company plans to expand access to ISEMBYLD globally, in up to 50 countries worldwide, subject to regulatory approvals.